The cancer genetic testing services provider, NeoGenomics has launched the first molecular assay, NeoType CLL for clinical use in the US, which detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1). The assay will offer ...
Tags: molecular assay, clinical research, clinical development
TG Therapeutics and Ildong Pharmaceutical have signed a licensing deal to develop and commercialize an oncology candidate, Ublituximab, in South Korea and Southeast Asia. Under the contract, Ildong gains Ublituximab development rights in ...
Tags: TG, Ildong Pharmaceutical, Ublituximab
Teva Pharmaceutical has received US Food and Drug Administration(FDA)approval for Synribo injection to treat adult patients with chronic phase(CP)or accelerated phase(AP)chronic myeloid leukemia(CML)with resistance and/or intolerance to ...
Tags: Teva Synribo Injection, US FDA, Teva Pharmaceutical, chronic phase
Clinical-stage biopharmaceutical company OXiGENE's acute myelogenous leukemia (AML) drug candidate, OXi4503, has received FDA orphan drug status. The second-generation anticancer agent with a dual-mechanism vascular disrupting feature ...
The US Patent and Trademark Office (USPTO) has issued a notice of allowance for CytRx Corporation's patent application covering a pharmaceutical composition of tamibarotene in capsule form. Tamibarotene is an orally available, ...
Tags: notice of allowance, patent application, tamibarotene, USPTO
Genmab and GlaxoSmithKline (GSK) have announced the submission of a new drug application (NDA) for Arzerra (ofatumumab) to the Japanese Ministry of Health, Labor and Welfare (MHLW). Arzerra (ofatumumab) is submitted for the approval ...
Tags: new drug application, Arzerra, chronic lymphocytic leukemia
First, starting in 2011, China will implement the Twelfth Five-Year Plan, China's sustained growth and development, rapid urbanization to enhance the period of a year will increase by one percentage point. The country will have about 13 ...
Tags: stone